Relay Therapeutics
RLAY
$19.37
-0.72%
Relay Therapeutics is a clinical-stage precision medicine company leveraging its proprietary Dynamo platform to discover and develop small-molecule drugs targeting previously intractable proteins in precision oncology and genetic diseases. The company distinguishes itself through an integrated computational and experimental approach that aims to accelerate drug discovery and improve success rates. Current investor attention centers on the recent positive Phase 2 trial results for its lead candidate RLY-2608, which drove a significant stock surge and bullish analyst upgrades, while the broader narrative focuses on the platform's potential to generate a pipeline of high-value therapies.…
RLAY
Relay Therapeutics
$19.37
Related headlines
RLAY 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Relay Therapeutics's 12-month outlook, with a consensus price target around $25.08 and implied upside of +29.5% versus the current price.
Average Target
$25.08
0 analysts
Implied Upside
+29.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$20 - $32
Analyst target range
Insufficient analyst coverage available. Only 7 analysts cover the stock, which is relatively low for a biotech of this market cap. The consensus EPS estimates range from -$0.20 to -$0.09, with an average of -$0.12, reflecting ongoing losses. Revenue estimates average $466.6 million, with a wide range of $365.2 million to $686.3 million, indicating high uncertainty about future product sales. The limited coverage implies that the stock may experience higher volatility and less efficient price discovery, as fewer analysts are providing guidance and price targets. Investors should rely more on clinical trial data and pipeline milestones for valuation.
Drowning in data?
Find the real signal!
RLAY Technical Analysis
Relay Therapeutics is in a powerful sustained uptrend, with the stock surging 436.3% over the past year. The current price of $20.005 sits at 96.2% of its 52-week range ($3.025 to $20.79), indicating strong momentum and near all-time highs. This positioning suggests the market is pricing in continued positive catalysts, though it also raises the risk of overextension. Short-term momentum is accelerating dramatically, with a 1-month gain of 48.3% and a 3-month gain of 33.9%, far outpacing the S&P 500's 4.1% and 11.1% returns over the same periods. The 1-month relative strength of 44.2% versus the S&P 500 underscores the stock's exceptional recent outperformance, which may be driven by the Phase 2 data catalyst. The 52-week low of $3.025 provides a distant support level, while the 52-week high of $20.79 is the immediate resistance. A breakout above $20.79 would signal further upside, while a pullback below recent support near $17 could indicate profit-taking. With a beta of 1.682, the stock is 68% more volatile than the market, amplifying both upside and downside risks for investors.
Beta
1.68
1.68x market volatility
Max Drawdown
-28.1%
Largest decline past year
52-Week Range
$3-$21
Price range past year
Annual Return
+432.1%
Cumulative gain past year
| Period | RLAY Return | S&P 500 |
|---|---|---|
| 1m | +28.7% | +0.1% |
| 3m | +15.6% | +5.7% |
| 6m | +163.5% | +8.5% |
| 1y | +432.1% | +20.3% |
| ytd | +136.8% | +10.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RLAY Fundamental Analysis
Relay Therapeutics is a pre-revenue clinical-stage biotech, with no product sales yet. The most recent quarterly revenue is not available, but the company's focus is on advancing its pipeline through clinical trials. The lack of revenue means the growth trajectory is binary, dependent on clinical and regulatory milestones. The recent positive Phase 2 data for RLY-2608 is a key catalyst that could lead to future revenue if the drug advances to approval. The company is unprofitable, with a trailing net margin of -1800.6% and an operating margin of -1971.6%. Net income is negative, as reflected by the EPS of -$0.19. However, gross margin is 76.8%, indicating that if the company generates revenue, it could have attractive product-level profitability. The balance sheet is strong, with a current ratio of 22.6, suggesting ample liquidity to fund operations. Debt-to-equity is a low 0.057, indicating minimal leverage. Free cash flow is negative (PCF ratio of -6.17), but the company's cash position (implied by high current ratio) provides a runway. ROE is -48.8%, reflecting the net loss relative to equity, which is typical for clinical-stage biotechs.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RLAY Overvalued?
Since net income is negative, the price-to-sales (PS) ratio is the primary valuation metric. The trailing PS ratio is 94.5x, which is extremely high, reflecting the market's expectation of future revenue growth from the pipeline. A forward PS ratio is not available, but the PEG ratio of 0.17 suggests that if earnings growth materializes, the stock could be undervalued on a growth-adjusted basis. Compared to the biotechnology industry average PS ratio (typically around 5-10x), Relay trades at a massive premium, reflecting its platform potential and recent clinical success. However, this premium is common for pre-revenue biotechs with promising pipelines. Historical PS data is not available, but given the stock's 52-week low of $3.025, the current valuation is near the high end of its historical range, indicating that the market is pricing in optimistic expectations for RLY-2608 and other pipeline assets.
PE
-5.3x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-5.1x
Enterprise Value Multiple
